Intellia Therapeutics’ (NTLA) Buy Rating Reaffirmed at Canaccord Genuity Group
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Canaccord Genuity Group in a research note issued on Tuesday,Benzinga reports. They presently have a $90.00 price target on the stock. A number of other research analysts have also recently commented on NTLA. The Goldman Sachs Group reduced […]
More Stories
Ford’s Stock Stalls as Analysts Blame Profitability
By Panos Mourdoukoutas Ford’s stock performance has been subdued lately despite rising vehicle sales. Analysts attribute this to the company’s...
Musk Mulls New Political Party Amid Feud With Trump
By Tom Ozimek Elon Musk is considering launching a new political party in the wake of his public fallout with...
Coco Gauff Defeats Top-Ranked Aryna Sabalenka to Win Her First French Open Title
By The Associated Press PARIS—Coco Gauff has won the French Open for the first time by defeating top-ranked Aryna Sabalenka...
Citigroup Reverses Course on Controversial Firearm Policies
By Naveen Athrappully Citigroup reversed its policy requiring retail business clients to refrain from selling firearms to those who haven’t...
“One Big Beautiful Bill” or “Debt Slavery Act”? Inside the High-Stakes Battle Over Trump’s Economic Agenda
By Stephen Zogopoulos, USNN World News On May 22, 2025, the U.S. House of Representatives narrowly passed the One Big...
Rubrik (NYSE:RBRK) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says
Rubrik (NYSE:RBRK – Free Report) had its target price hoisted by Wells Fargo & Company from $80.00 to $125.00 in...